Massive study of 22 million seniors reveals Real-World power of new pneumonia vaccine
NCT ID NCT06782282
First seen Nov 21, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study checks how well the Prevnar 20 (PCV20) vaccine works in real life for people 65 and older. Researchers will look at medical records from over 22 million Medicare patients to see if the vaccine lowers the risk of serious lung infections like pneumonia. No new treatments are given—the study simply compares those who got the vaccine to those who did not.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMUNITY-ACQUIRED PNEUMONIA (CAP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer United States
New York, New York, 10017, United States
Conditions
Explore the condition pages connected to this study.